Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Lewy body dementia

Topic: Brain proteins, microglia and lab models

Plain-language summary

In this review, we outline the significant roles of necroptosis and its molecular mechanisms in the pathological process of VaD, with a particular focus on the role of necroptosis in modulating neuroinflammation and exacerbating the disruption of BBB permeability in VaD, and elaborate on the molecular regulatory mechanisms and the centrally involved cells of necroptosis mediated by tumor necrosis factor-α in neuroinflammation in VaD. We also analyze the possibility and specific strategy that targeting necroptosis would help inhibit neuroinflammation and BBB destruction in VaD. With a focus on necroptosis, this study delved into its impact on the pathological changes and prognosis of VaD to provide new treatment ideas.

What this study adds

Evidence grade: Low

This review outlines the roles of necroptosis in vascular dementia, focusing on neuroinflammation and blood-brain barrier disruption, and analyzes the possibility of targeting necroptosis as a treatment strategy. It provides new treatment ideas but no confirmed therapy or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Qiu, Y., Cheng, L., Xiong, Y., Liu, Z., Shen, C., Wang, L., et al. (2025). Advances in the Study of Necroptosis in Vascular Dementia: Focus on Blood–Brain Barrier and Neuroinflammation. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70224

Vancouver

Qiu Y, Cheng L, Xiong Y, Liu Z, Shen C, Wang L, et al. Advances in the Study of Necroptosis in Vascular Dementia: Focus on Blood–Brain Barrier and Neuroinflammation. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70224. PMID: 39915907.

BibTeX

@article{qiu2025-39915907,
  author  = {Qiu, Yuemin and Cheng, Lin and Xiong, Yinyi and Liu, Ziying and Shen, Chunxiao and Wang, Liangliang and Lu, Yujia and Wei, Shufei and others},
  title   = {{Advances in the Study of Necroptosis in Vascular Dementia: Focus on Blood–Brain Barrier and Neuroinflammation}},
  journal = {CNS Neuroscience \& Therapeutics},
  year    = {2025},
  doi     = {10.1111/cns.70224},
  pmid    = {39915907},
  url     = {https://doi.org/10.1111/cns.70224}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This review outlines the roles of necroptosis in vascular dementia, focusing on neuroinflammation and blood-brain barrier disruption, and analyzes the possibility of targeting necroptosis as a treatment strategy. It provides new treatment ideas but no confirmed therapy or cure.

Study details

How this study scored 37/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 37 of 100.37 of 100 points earned63 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (CNS Neuroscience & Therapeutics)
Journal's citation record 1 / 4 CNS Neuroscience & Therapeutics: journal h-index 120 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 12 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.0 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 3.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Xiaorong Zhang: h-index 5 (OpenAlex, whole career)
Institution's track record 0 / 3 Jiujiang University: institution h-index 109 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39915907)
Free to read 2 / 2 Free to read
Total 37 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.

Related studies in Lewy body dementia from nearby years

Also tagged “small”

900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Lewy body dementia

See all studies in Lewy body dementia →